secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000950170-25-025626
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences regains Nasdaq compliance and advances PRIME Phase 1b CKD study
--------------------------------------------------------------------------------

- Nasdaq confirmed REVB common stock meets minimum bid price and all continued listing requirements.
- Company cannot use 180-day grace period if bid price falls below $1.00 again; would receive delisting letter but may request hearing.
- PRIME Phase 1b study of Gemini IV in Stage 3-4 CKD patients has commenced, enrolling up to 40 patients across 5 cohorts.
- CEO James Rolke highlighted Nasdaq listing for liquidity, capital access, and talent retention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025025626/0000950170-25-025626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025025626/revb-20250219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-025626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer